# Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)

> **NCT01015352** · PHASE2 · COMPLETED · sponsor: **Groupe Francophone des Myelodysplasies** · enrollment: 98 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Epoetin beta

## Key facts

- **NCT ID:** NCT01015352
- **Lead sponsor:** Groupe Francophone des Myelodysplasies
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2014-03-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01015352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01015352, "Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01015352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*